DRR168577
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- ALLOGRAFT_REJECTION+0.640
- INTERFERON_GAMMA_RESPONSE+0.620
- IL6_JAK_STAT3_SIGNALING+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- COMPLEMENT+0.480
- INFLAMMATORY_RESPONSE+0.480
- KRAS_SIGNALING_UP+0.410
- TNFA_SIGNALING_VIA_NFKB+0.360
- HEDGEHOG_SIGNALING+0.350
Top 10 suppressed
- MYC_TARGETS_V2-0.620
- MYC_TARGETS_V1-0.520
- OXIDATIVE_PHOSPHORYLATION-0.510
- CHOLESTEROL_HOMEOSTASIS-0.440
- GLYCOLYSIS-0.400
- E2F_TARGETS-0.350
- DNA_REPAIR-0.340
- MTORC1_SIGNALING-0.340
- ADIPOGENESIS-0.330
- PEROXISOME-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613789 | — | A | 0.945 |
| 2 | 767fc312-2c66-43f7-b78e-bf79e03e3a0a | — | — | 0.930 |
| 3 | 6dfa748c-af43-469f-a98b-8472a4132739 | — | — | 0.926 |
| 4 | TCGA-55-6979-01A-11R-1949-07 | — | cohortA1 | 0.920 |
| 5 | C3N-00433 | — | cohortMD2 | 0.918 |
| 6 | cfbdbfeb-7550-46dc-bd3b-bf85c4a14443 | — | — | 0.916 |
| 7 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.916 |
| 8 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.915 |
| 9 | TCGA-AQ-A7U7-01A-22R-A352-07 | — | D | 0.914 |
| 10 | SRR12202441 | — | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.640 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.620 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.090 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |